Drug Science publish regular articles that analyse developments in drug science and policy to highlight areas of improvement based on evidence

In this update, find out what GPs think about medical cannabis as we celebrate 1000 patients joining Project Twenty21. We share updates on the project, including new clinics and data insights, as well as initiatives working to improve medical cannabis in the UK. We also announce new events related to the…

Ketamine, 2-(2-chlorophenyl)-2-(methylamino)-cyclohexan-1-one, is a dissociative sedative with analgesic and anaesthetic properties, now being investigated as an antidepressant, alone and as part of ketamine-assisted therapy. Discovered in 1962 by Calvin L. Stevens, and first tested on humans in 1964, ketamine was approved for medical use by the USA in 1970 and remains…

In this update, we reveal a new clinical analysis of epilepsy T21 epilepsy patients and share the latest data and patient stories from Project Twenty21. We also announce new events related to the project and medical cannabis more generally. Learn more about Project Twenty21 Over the past month, we’ve been working…

YouGov poll results on psilocybin therapy and the government decision to reschedule psilocybin

Summary Full Report Survey Data Does the UK support psilocybin research?Public perceptions of psilocybin-assisted therapy have been revealed in a new YouGov poll, commissioned by Drug Science. This is the first nationally representative poll of UK attitudes towards the medicalisation of psilocybin and support for policy changes (such as rescheduling psilocybin)…

Drug usage is currently extremely high and it is particularly prevalent amongst those suffering from mental health conditions. Despite this, many healthcare workers are not trained to recognise the signs of substance misuse and are often unaware of how to treat this distinctive patient group appropriately. Psychiatric patients who use drugs are…